Physician profile
Priya Bhatt
NPI 1881197283
$2,535.32
in general payments reported to CMS, 2019-2025
23 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $301 · 2023: $771 · 2024: $744 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644 · Education: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.03 |
| Education | $459.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $314.83 | 2023-2025 | Tivdak, Tukysa |
| Merck Sharp & Dohme LLC | $304.86 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Lilly USA, LLC | $240.00 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Astrazeneca Pharmaceuticals Lp | $215.16 | 2023-2025 | Enhertu, Tagrisso |
| Pfizer INC. | $193.49 | 2023-2025 | |
| Genentech USA, INC. | $164.39 | 2022-2025 | Phesgo, Itovebi, Tecentriq |
| Novartis Pharmaceuticals Corporation | $150.97 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $145.78 | 2022 | |
| Celgene Corporation | $127.01 | 2021-2022 | |
| Janssen Biotech, INC. | $112.48 | 2022-2025 | Talvey, Darzalex, Rybrevant |
| Daiichi Sankyo INC. | $98.32 | 2024-2025 | Enhertu |
| Astellas Pharma US INC | $79.00 | 2023 | |
| Stemline Therapeutics INC. | $64.93 | 2024-2025 | Orserdu |
| Myriad Genetic Laboratories, INC. | $47.29 | 2024-2025 | Myrisk |
| Glaxosmithkline, LLC. | $42.66 | 2023-2025 | Ojjaara, Zejula, Jemperli |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $37.30 | 2024 | |
| Dendreon Pharmaceuticals LLC | $34.49 | 2022 | |
| Puma Biotechnology, INC. | $33.28 | 2023-2025 | Nerlynx |
| Immunogen, INC. | $31.09 | 2023 | Elahere |
| Caris Mpi, INC. | $30.07 | 2025 | Mi Cancer Seek |
| Amgen INC. | $24.37 | 2021 | |
| Novo Nordisk INC | $23.55 | 2023 | Rybelsus |
| Emd Serono, INC. | $20.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Bhatt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.